Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Musculoskeletal
Study Phase : Undisclosed
Recipient : University of Nottingham
Deal Size : Inapplicable
Deal Type : Inapplicable
Protein Digestibility and Bioavailability Study In Older Men Using Isotope Tracers
Details : This drug candidate is currently being evaluated in clinical studies for the treatment of Sarcopenia.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 26, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Musculoskeletal
Highest Development Status : Undisclosed
Recipient : University of Nottingham
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Smoflipid
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Smoflipid is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Child Nutrition Disorders.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 22, 2023
Lead Product(s) : Smoflipid
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tocilizumab
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Tyenne®*, Fresenius Kabi’s Tocilizumab Biosimilar, Receives European Commission Approval
Details : Tyenne (tocilizumab biosimilar) is a recombinant humanized monoclonal antibody targeting IL-6R, which specifically binds to sIL-6R and mIL-6R and inhibits signaling mediated by sIL-6R or mIL-6R. It is approved for the treatment of RA, sJIA, and CRS.
Product Name : Tyenne
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
September 19, 2023
Lead Product(s) : Tocilizumab
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ganirelix
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Expanding Access to Women’s Health Fresenius Kabi Launches Generic Fertility Treatment
Details : Ganirelix Acetate Injection is indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation.
Product Name : Antagonä-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 10, 2023
Lead Product(s) : Ganirelix
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diazepam
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Diazepam Injection is a ready-to-administer prefilled syringes which is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 31, 2023
Lead Product(s) : Diazepam
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lidocaine
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Recipient : University of Malaya
Deal Size : Inapplicable
Deal Type : Inapplicable
Accelerated Recovery Following Opioid-free Anaesthesia in Supratentorial Craniotomy
Details : Lidocaine is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 12, 2023
Lead Product(s) : Lidocaine
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Recipient : University of Malaya
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lacosamide
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Fresenius Kabi Lacosamide Injection, USP is an approved treatment option for partial-onset seizures in patients 17 years of age and older and is available in 200 mg per 20 mL single-dose vials.
Product Name : Lacosamide-Generic
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 15, 2022
Lead Product(s) : Lacosamide
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Adalimumab
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Fresenius Kabi Receives U.S. FDA Approval for Biosimilar Idacio® (adalimumab)
Details : Idacio® (adalimumab), is a tumor necrosis factor (TNF) blocker and a biosimilar to Humira®. Adalimumab is a monoclonal antibody that binds TNFα and blocks its general cytokine effects.
Product Name : Idacio
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
December 14, 2022
Lead Product(s) : Adalimumab
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pralatrexate
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pralatrexate injection is a dihydrofolate reductase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
Product Name : Pralatrexate-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 08, 2022
Lead Product(s) : Pralatrexate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegfilgrastim
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Fresenius Kabi Receives U.S. FDA Approval for Biosimilar Stimufend® (pegfilgrastim-fpgk)
Details : U.S.FDA has approved its biosimilar, Stimufend® (pegfilgrastim-fpgk), for use in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Product Name : Stimufend
Product Type : Protein
Upfront Cash : Inapplicable
September 06, 2022
Lead Product(s) : Pegfilgrastim
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable